Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-813160 + 5-fluorouracil + leucovorin + irinotecan
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a **combination regimen** consisting of BMS-813160, a potent and selective small molecule dual antagonist of the chemokine receptors CCR2 and CCR5[4], and the chemotherapeutic agents **5-fluorouracil**, **leucovorin**, and **irinotecan** (often known together as FOLFIRI)[1][2]. BMS-813160 modulates the tumor microenvironment by blocking CCR2 and CCR5 on monocytes and tumor-associated macrophages, intended to reduce immunosuppressive cell infiltration and migration, potentially enhancing antitumor responses with chemotherapy[4]. 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase, leucovorin enhances the effect of 5-fluorouracil, and irinotecan is a topoisomerase I inhibitor that prevents DNA replication in cancer cells. This combination has been investigated in advanced or metastatic colorectal and pancreatic cancers[1][2].
- Other names
- FOLFIRI + BMS-813160
02
Targets
CCR5 (C-C chemokine receptor type 5)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on BMS-813160 + 5-fluorouracil + leucovorin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-813160 + 5-fluorouracil + leucovorin + irinotecan.